Area of research
Cancer Research · Molecular Biology
Research interest
Research interests include Cancer-related molecular mechanisms research, RNA modifications and cancer, Cancer Immunotherapy and Biomarkers, and MicroRNA in disease regulation.
Wave succession in the pandemic clone of Vibrio parahaemolyticus driven by gene loss.
Glutamine metabolic competition drives immunosuppressive reprogramming of intratumour GPR109A<sup>+</sup> myeloid cells to promote liver cancer progression.
Multimodal integration of liquid biopsy and radiology for the noninvasive diagnosis of gallbladder cancer and benign disorders
Mesenchymal stem cell-derived extracellular vesicles alleviate autism by regulating microglial glucose metabolism reprogramming and neuroinflammation through PD-1/PD-L1 interaction
The interplay between tissue‐resident microbiome and host proteins by integrated multi‐omics during progression of colorectal adenoma to carcinoma
Wave succession in the pandemic clone of Vibrio parahaemolyticus driven by gene loss
scGALA advances graph link prediction-based cell alignment for comprehensive data integration and harmonization.
[Application of Digital Nutrition Technologies in Adult Weight Management].
Detecting circulating tumor DNA in archived whole blood samples in patients undergoing treatment for primary cutaneous melanoma
Glutamine metabolic competition drives immunosuppressive reprogramming of intratumour GPR109A<sup>+</sup> myeloid cells to promote liver cancer progression
Targeting KDM4 family epigenetically triggers antitumour immunity via enhancing tumour-intrinsic innate sensing and immunogenicity.
GOLM1 dictates acquired Lenvatinib resistance by a GOLM1-CSN5 positive feedback loop upon EGFR signaling activation in hepatocellular carcinoma
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells
Cancer germline predisposing variants and late mortality from subsequent malignant neoplasms among long-term childhood cancer survivors: a report from the St Jude Lifetime Cohort and the Childhood Cancer Survivor Study
<i>Eucommia</i> Bark/Leaf Extract Improves Lipid Metabolism Disorders by Affecting Intestinal Microbiota and Microbiome-Host Interaction in HFD Mice.
Caspase-9 inhibition triggers Hsp90-based chemotherapy-mediated tumor intrinsic innate sensing and enhances antitumor immunity.
Effects of obesity with reduced 25(OH)D levels on bone health in elderly Chinese people: a nationwide cross-sectional study
Incidence and Predictive Factors of New Onset Postoperative Sacroiliac Joint Pain After Posterior Lumbar Fusion Surgery for Degenerative Lumbar Disease
Enlarged posterior column osteotomy plus intervertebral cage strutting as a exploratory surgery for lumbosacral Nerve bowstring disease: a retrospective retrospective study
Multi-kingdom microbiota analyses identifybacterial–fungal interactions and biomarkers of colorectal cancer acrosscohorts
Multi-kingdom microbiota analyses identify bacterial-fungal interactions and biomarkers of colorectal cancer across cohorts.
Long-term exposure to genistein inhibits the proliferation of gallbladder cancer by downregulating the MCM complex
Hounsfield Unit for Assessing Bone Mineral Density Distribution Within Cervical Vertebrae and Its Correlation With the Intervertebral Disc Degeneration
Long noncoding RNA LHFPL3-AS2 suppresses metastasis of non-small cell lung cancer by interacting with SFPQ to regulate TXNIP expression
Mycobiome Dysbiosis in Women with Intrauterine Adhesions.
A human iPSC-array-based GWAS identifies a virus susceptibility locus in the NDUFA4 gene and functional variants
Mutagenic Characteristics of Six Heavy Metals in <i>Escherichia coli</i>: The Commonality and Specificity.
Molecular Mechanism of Xingnao Kaiqiao Pill for Perioperative Neurocognitive Disorder and Its Correlation With Immune and Inflammatory Signaling Pathways Based on Network Pharmacology and Molecular Docking
EGFR activation limits the response of liver cancer to lenvatinib